Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
According to Strides Pharma Science Limited's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.44. At the end of 2022 the company had a P/B ratio of 1.17.
Year | P/B ratio |
---|---|
2023 | 3.44 |
2022 | 1.17 |
2021 | 1.32 |
2020 | 2.73 |
2019 | 1.14 |
2018 | 1.61 |
2017 | 2.34 |
2016 | 3.40 |
2015 | 3.17 |
2014 | 8.64 |
2013 | 2.13 |
2012 | 4.53 |
2011 | 2.45 |
2010 | 2.93 |
2009 | 2.41 |
2008 | 1.80 |
2007 | 8.59 |
2006 | 8.18 |
2005 | 8.34 |
2004 | 8.53 |